Anika Therapeutics (ANIK) Change in Receivables (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Change in Receivables data on file, last reported at $2.2 million in Q1 2026.

• Change in Receivables for Q1 2026 came in at $2.2 million, up 171.85% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.8 million (up 273.13% YoY), and the FY2025 annual result was -$408000.0, up 87.88% from the prior year.
• Change in Receivables advanced to $2.2 million in Q1 2026 per ANIK's latest filing, from $1.5 million in the prior quarter.
• Over five years, Change in Receivables peaked at $6.2 million in Q2 2023 and troughed at -$4.8 million in Q3 2024.
• A 5-year average of $314176.5 and a median of $1.1 million in 2023 frame the typical range for Change in Receivables.
• The sharpest annual moves came in 2023 and 2024: Change in Receivables tumbled 959.27% in 2023, then surged 196.38% in 2024.
• A 5-year view of Change in Receivables shows it stood at $647000.0 in 2022, then jumped by 70.63% to $1.1 million in 2023, then surged by 196.38% to $3.3 million in 2024, then sank by 52.78% to $1.5 million in 2025, then soared by 41.1% to $2.2 million in 2026.
• Business Quant data shows ANIK's Change in Receivables at $2.2 million in Q1 2026, $1.5 million in Q4 2025, and -$1.3 million in Q3 2025.